Lyn Baranowski is the chief executive officer of Avalyn Pharma, a clinical-stage biopharmaceutical company focused on developing targeted medicines for patients with rare lung diseases in need of better therapeutic options.  Avalyn currently has two programs in clinical development: inhaled versions of IPF & ILD medicines pirfenidone and nintedanib.  With inhaled delivery, Avalyn’s platform promises to fundamentally improve the product profile of the molecules in two ways: by increasing lung exposure at smaller doses than the oral forms, potentially improving efficacy, while decreasing systemic exposure, resulting in improved tolerability / AE profiles.

Lyn has more than two decades of experience leading a vast array of functions in biotech, big pharma, and venture capital firms with a focus in the respiratory therapeutic area. Prior to joining Avalyn, Ms. Baranowski served as chief operating officer at Altavant Sciences, a biopharmaceutical company that successfully built and developed a portfolio of therapies for rare respiratory diseases prior to its 2019 acquisition by Sumitomo Dainippon. Earlier in her career, she served in senior-level corporate development and commercial roles, including vice president of commercial development at Pearl Therapeutics, which successfully developed a portfolio of asthma & COPD medicines prior to its sale to AstraZeneca for $1.15 Billion in 2013; and vice president in a healthcare-focused venture capital firm based in New York. She had previously held roles in business development, marketing and public affairs with Novartis Pharmaceuticals in Switzerland and the U.S.

She earned an MBA from Harvard Business School and a Bachelor of Arts from American University. In addition to her role at Avalyn, Ms. Baranowski serves on the planning committee for the American Thoracic Society’s Respiratory Innovation Summit, an annual meeting that unites the innovators, investors, and clinicians who are leading the fight to create powerful new treatments for deadly and crippling diseases of the lungs and airways.